Literature DB >> 21801687

Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.

Jehonathan H Pinthus1, Kaitlyn F Whelan, Daniel Gallino, Jian-Ping Lu, Nathan Rothschild.   

Abstract

Central to the malignant behaviour that endows cancer cells with growth advantage is their unique metabolism. Cancer cells can process nutrient molecules differently from normal cells and use it to overcome stress imposed on them by various therapies. This metabolic conversion is controlled by specific genetic mutations that are associated with activation of oncogenes and loss of tumour suppressor proteins. Understanding these processes is important as it can lead to the discovery of biomarkers that can predict the aggressiveness of the disease and its response to therapy, and even more importantly, to the development of novel therapeutics. A classic tumour in this respect is clear-cell renal cell carcinoma (RCC). In this review, we will begin with a brief summary of normal cellular bioenergetic pathways, which will be followed by a description of the characteristic metabolism of glucose and lipids in clear-cell RCC cells and its clinical implications. Data relating to the potential effect of dietary nutrients on RCC will also be reviewed along with potential therapies targeted at interrupting specific metabolic pathways in clear-cell RCC.

Entities:  

Year:  2011        PMID: 21801687      PMCID: PMC3147044          DOI: 10.5489/cuaj.10196

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  75 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

Authors:  George V Thomas; Chris Tran; Ingo K Mellinghoff; Derek S Welsbie; Emily Chan; Barbara Fueger; Johannes Czernin; Charles L Sawyers
Journal:  Nat Med       Date:  2005-12-11       Impact factor: 53.440

3.  NADP+ reduction by human lymphocytes.

Authors:  A Klein; A W Chan; B U Caplan; A Malin
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

Review 4.  VHL and HIF signalling in renal cell carcinogenesis.

Authors:  Marcella M Baldewijns; Iris J H van Vlodrop; Peter B Vermeulen; Patricia M M B Soetekouw; Manon van Engeland; Adriaan P de Bruïne
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

Review 5.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

Review 6.  Monitoring response to treatment in patients utilizing PET.

Authors:  Norbert E Avril; Wolfgang A Weber
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

7.  Rapamycin down-regulates LDL-receptor expression independently of SREBP-2.

Authors:  Laura J Sharpe; Andrew J Brown
Journal:  Biochem Biophys Res Commun       Date:  2008-07-09       Impact factor: 3.575

Review 8.  Fatty acid synthase inhibitors: new directions for oncology.

Authors:  Steven J Kridel; W Todd Lowther; Charles W Pemble
Journal:  Expert Opin Investig Drugs       Date:  2007-11       Impact factor: 6.206

9.  Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma.

Authors:  Akio Horiguchi; Tomohiko Asano; Takako Asano; Keiichi Ito; Makoto Sumitomo; Masamichi Hayakawa
Journal:  J Urol       Date:  2008-07-18       Impact factor: 7.450

10.  Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.

Authors:  David Lyrdal; Marianne Boijsen; Madis Suurküla; Sven Lundstam; Ulrika Stierner
Journal:  Nucl Med Commun       Date:  2009-07       Impact factor: 1.690

View more
  26 in total

1.  Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.

Authors:  Parisa Farzam; Johannes Johansson; Miguel Mireles; Gabriela Jiménez-Valerio; Mar Martínez-Lozano; Regine Choe; Oriol Casanovas; Turgut Durduran
Journal:  Biomed Opt Express       Date:  2017-04-19       Impact factor: 3.732

Review 2.  The Metabolism of Renal Cell Carcinomas and Liver Cancer.

Authors:  Tu Nguyen; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

3.  Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.

Authors:  Denise R Minton; Leiping Fu; Nigel P Mongan; Maria M Shevchuk; David M Nanus; Lorraine J Gudas
Journal:  Clin Cancer Res       Date:  2016-01-18       Impact factor: 12.531

Review 4.  Hypoxia and fatty liver.

Authors:  Tomohiro Suzuki; Satoko Shinjo; Takatomo Arai; Mai Kanai; Nobuhito Goda
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

5.  The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma.

Authors:  Sheliyan Raveenthiran; Rachel Esler; John Yaxley; Sam Kyle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-23       Impact factor: 9.236

6.  Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.

Authors:  Leiping Fu; Denise R Minton; Tuo Zhang; David M Nanus; Lorraine J Gudas
Journal:  Mol Cancer Res       Date:  2015-02-25       Impact factor: 5.852

7.  Loss of p27 upregulates MnSOD in a STAT3-dependent manner, disrupts intracellular redox activity and enhances cell migration.

Authors:  Dongyun Zhang; Yulei Wang; Yuguang Liang; Min Zhang; Jinlong Wei; Xiao Zheng; Fei Li; Yan Meng; Nina Wu Zhu; Jingxia Li; Xue-Ru Wu; Chuanshu Huang
Journal:  J Cell Sci       Date:  2014-04-11       Impact factor: 5.285

8.  MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma.

Authors:  Elizabeth Ellen Jones; Thomas W Powers; Benjamin A Neely; Lisa H Cazares; Dean A Troyer; Alexander S Parker; Richard R Drake
Journal:  Proteomics       Date:  2014-03-03       Impact factor: 3.984

9.  Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.

Authors:  Christina A von Roemeling; Laura A Marlow; Johnny J Wei; Simon J Cooper; Thomas R Caulfield; Kevin Wu; Winston W Tan; Han W Tun; John A Copland
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531

10.  The Heterogeneity Metabolism of Renal Cell Carcinomas.

Authors:  Mohammadreza Zarisfi; Tu Nguyen; Jessie R Nedrow; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.